Journal of the advanced practitioner in oncology最新文献

英文中文

JADPRO Live Virtual 2021 JADPRO Live Virtual 2021

Journal of the advanced practitioner in oncology

Pub Date : 2021-11-01 DOI: 10.6004/jadpro.2021.12.8.1

Beth Faiman

引用次数: 0

ASH Highlights and Commentary: Additional Topics of Interest ASH亮点和评论:其他感兴趣的主题

Journal of the advanced practitioner in oncology

Pub Date : 2021-04-01 DOI: 10.6004/jadpro.2021.12.3.30

PhD Aprn Aocn® Sara Tinsley, PhD Anp-C Aocn Sandra E. Kurtin

Dr. Tinsley provides insight for APs on the use of pevonedistat, a new small-molecule inhibitor. Dr. Kurtin considers the use of the CRISPR technique to detect COVID-19 in patients with hematologic malignancies and data from a retrospective observational cohort study describing the disease burden of primary cold agglutinin disease.

Tinsley博士为APs提供了关于pevonedistat(一种新的小分子抑制剂)使用的见解。Kurtin博士考虑使用CRISPR技术检测血液学恶性肿瘤患者中的COVID-19，以及来自描述原发性冷凝集素疾病负担的回顾性观察性队列研究的数据。

引用次数: 0

ASH Highlights and Commentary: Multiple Myeloma ASH亮点与评论：多发性骨髓瘤

Journal of the advanced practitioner in oncology

Pub Date : 2021-04-01 DOI: 10.6004/jadpro.2021.12.3.28

B. Faiman, Aprn-Bc, Aocn, Faan

Dr. Faiman considers the use of qualitative interviews to understand the patient perspective on the clinical benefits and tolerability of belamaf. She also highlights the safety profile and noninferiority of subcutaneous daratumumab compared with IV daratumumab, as described in the APOLLO trial. Finally, Dr. Faiman emphasizes the importance of achieving MRD negativity measured by multiparameter flow cytometry and next-generation sequencing.

Faiman博士考虑使用定性访谈来了解患者对belamaf临床益处和耐受性的看法。她还强调了皮下注射达拉图单抗与静脉注射达拉图单抗相比的安全性和非劣效性，如APOLLO试验中所述。最后，Faiman博士强调了通过多参数流式细胞术和下一代测序测量MRD阴性的重要性。

引用次数: 0

ASH Highlights and Commentary: Chronic Lymphocytic Leukemia and Lymphomas ASH亮点与评论：慢性淋巴细胞白血病和淋巴瘤

Journal of the advanced practitioner in oncology

Pub Date : 2021-04-01 DOI: 10.6004/jadpro.2021.12.3.29

PhD Aprn Aocn® Sara Tinsley, PhD Anp-C Aocn Sandra E. Kurtin

125 Five-Year Analysis of MURANO Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx) Arnon P. Kater, MD, PhD, Thomas J. Kipps, MD, PhD, Barbara Eichhorst, MD, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, James D’Rozario, Carolyn Owen, MD, FRCPC, Sarit E Assouline, MD, MSc, Nicole Lamanna, MD, Tadeusz J. Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, MD, PhD, Marco Montillo, Clemens Mellink, Brenda J. Chyla, Cameron Wilson, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, and John F. Seymour Visit https://doi.org/10.1182/blood-2020-136109 for a complete list of contributor affiliations and full graphics. Introduction: The randomized Phase III MURANO study (NCT02005471) compared fixed-duration VenR with standard bendamustine-rituximab (BR) in R/R CLL. Deep responses with uMRD were associated with superior progression-free survival (PFS) of VenR vs BR with 48 months (mo) follow-up (f/u). We now report long-term MRD kinetics and updated efficacy outcomes, including re-exposure to VenR (to be presented), with a 5 year (yr) median follow-up (clinical cutoff date May 8, 2020). Methods: As published, pts were randomized to VenR (Ven 400 mg daily for 2 yrs + standard dose R for the first 6 mo) or B (70 mg/m2)R (6 mo). A sub-study was introduced in 2018, allowing pts who developed progressive disease (PD) following Tx with BR or VenR to receive the MURANO VenR regimen. PFS was based on investigator assessment. Peripheral blood MRD was analyzed centrally by allele-specific oligonucleotide polymerase chain reaction and/or flow cytometry. Pts were categorized by MRD status as previously reported, using <10-4 threshold for uMRD. MRD conversion was defined as 2 consecutive assays detecting MRD or PD in pts who previously had uMRD. Genomic complexity (GC) and del(17p) status were assessed by array comparative genomic hybridization. GC was defined as ≥3 copy number variations (CNV). All p-values are descriptive. Results: 389 pts were enrolled (VenR, n=194; BR, n=195). With a median f/u of 59.2 (range, 0-71.5) mo, the PFS benefit with VenR over BR was sustained (HR, 0.19 [95% CI: 0.15-0.26]; p<0.0001). Median PFS was 53.6 (95% CI: 48.4-57.0) mo for VenR and 17.0 (95% CI: 15.5-21.7) mo for BR. For pts who completed the full 2 yrs of Ven Tx (n=130), PFS estimates 36 mo post-end of treatment (EOT) were ~51.1% (95% CI: 40.2-61.9). Overall survival (OS) benefit was maintained for pts treated with VenR vs BR (HR, 0.40 [95% CI: 0.26-0.62]; p<0.0001), with 5-yr OS estimates of 82.1% (95% CI: 76.4-87.8) for VenR and 62.2% (95% CI: 54.8-69.6) for BR. Improved OS outcome was observed among the VenR pts that reached EOT without PD and had uMRD (83/118) compared with those with MRD (35/118), with 3-yr post-EOT survival estimates of 95.3% (95% CI: 90.0-100.0) vs 85.0% (95% CI: 72.8-97.2

125 MURANO研究的五年分析显示复发/难治性慢性淋巴细胞白血病(R/R CLL)患者(Pts)在接受固定时间venetoclx - rituximab (VenR)治疗(Tx) (Arnon P. Kater, MD, PhD, Thomas J. Kipps, MD, PhD, Barbara Eichhorst, MD, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, James D 'Rozario, Carolyn Owen, MD, FRCPC, Sarit E Assouline, MD, MSc, Nicole Lamanna, MD, Tadeusz J. Robak，Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, MD, PhD, Marco Montillo, Clemens Mellink, Brenda J. Chyla, Cameron Wilson, Jenny Wu, Yanwen Jiang, Marcus lefeure, Michelle Boyer和John F. Seymour访问https://doi.org/10.1182/blood-2020-136109查看贡献者的完整列表和完整图表。介绍:随机III期MURANO研究(NCT02005471)比较了固定时间VenR与标准苯达莫司汀-利妥昔单抗(BR)治疗R/R CLL的疗效。在48个月(mo)随访(f/u)中，uMRD的深度缓解与VenR比BR的更好的无进展生存期(PFS)相关。我们现在报告长期MRD动力学和更新的疗效结果，包括再次暴露于VenR(待提交)，中位随访5年(临床截止日期为2020年5月8日)。方法:正如已发表的，患者被随机分配到VenR(每天400 mg，持续2年+标准剂量R，前6个月)或B (70 mg/m2)R(6个月)。2018年引入了一项子研究，允许在Tx合并BR或VenR后出现进行性疾病(PD)的患者接受MURANO VenR方案。PFS以研究者评估为基础。采用等位基因特异性寡核苷酸聚合酶链反应和/或流式细胞术集中分析外周血MRD。如前所述，根据MRD状态对患者进行分类，使用<10-4 uMRD阈值。MRD转换定义为连续2次检测先前患有uMRD的患者的MRD或PD。采用阵列比较基因组杂交技术评估基因组复杂性(GC)和del(17p)状态。GC定义为拷贝数变异(CNV)≥3。所有p值都是描述性的。结果:389名患者入组(VenR, n=194;BR, n = 195)。中位f/u为59.2(范围，0-71.5)个月，VenR比BR的PFS获益持续(HR, 0.19 [95% CI: 0.15-0.26];p < 0.0001)。VenR的中位PFS为53.6个月(95% CI: 48.4-57.0)， BR的中位PFS为17.0个月(95% CI: 15.5-21.7)。对于完成2年Ven Tx治疗的患者(n=130)，治疗结束后36个月的PFS估计(EOT)约为51.1% (95% CI: 40.2-61.9)。VenR与BR治疗的患者总生存期(OS)获益保持不变(HR, 0.40 [95% CI: 0.26-0.62];p<0.0001)， VenR的5年OS估计为82.1% (95% CI: 76.4-87.8)， BR的5年OS估计为62.2% (95% CI: 54.8-69.6)。与MRD(35/118)相比，达到EOT的VenR患者中，没有PD和uMRD(83/118)的OS结果有所改善，EOT后3年生存率分别为95.3% (95% CI: 90.0-100.0)和85.0% (95% CI: 72.8-97.2)(图1)。在EOT时uMRD的患者中，32/83没有显示PD，在5年更新时仍保持uMRD, 4/83有PD但未确诊MRD转换，47/83有MRD转换。从EOT到MRD转换的中位时间为19.4 (95% CI:8.7 - -28.3) J副词Pract杂志2021;12(3):17岁https://doi.org/10.6004/jadpro.2021.12.3.29 Th ar抽搐le dis三部te d u nd er Th e t m s o f t他Cr ea tiv e C om m s竞技场队伍的伊布·tio n n - d - C om m er中情局l n上er iva tiv e l冰ns e, wh我pe rm联合国再保险str ict教育没有nco m m er中情局l和濒死经历riv美国e,我说三部tio n,一个d r ep ro du cti在ed chromium的y m p rov ide d t他或igi na l w或k is p ro pe r ci te d。

{"title":"ASH Highlights and Commentary: Chronic Lymphocytic Leukemia and Lymphomas","authors":"PhD Aprn Aocn® Sara Tinsley, PhD Anp-C Aocn Sandra E. Kurtin","doi":"10.6004/jadpro.2021.12.3.29","DOIUrl":"https://doi.org/10.6004/jadpro.2021.12.3.29","url":null,"abstract":"125 Five-Year Analysis of MURANO Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx) Arnon P. Kater, MD, PhD, Thomas J. Kipps, MD, PhD, Barbara Eichhorst, MD, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, James D’Rozario, Carolyn Owen, MD, FRCPC, Sarit E Assouline, MD, MSc, Nicole Lamanna, MD, Tadeusz J. Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, MD, PhD, Marco Montillo, Clemens Mellink, Brenda J. Chyla, Cameron Wilson, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, and John F. Seymour Visit https://doi.org/10.1182/blood-2020-136109 for a complete list of contributor affiliations and full graphics. Introduction: The randomized Phase III MURANO study (NCT02005471) compared fixed-duration VenR with standard bendamustine-rituximab (BR) in R/R CLL. Deep responses with uMRD were associated with superior progression-free survival (PFS) of VenR vs BR with 48 months (mo) follow-up (f/u). We now report long-term MRD kinetics and updated efficacy outcomes, including re-exposure to VenR (to be presented), with a 5 year (yr) median follow-up (clinical cutoff date May 8, 2020). Methods: As published, pts were randomized to VenR (Ven 400 mg daily for 2 yrs + standard dose R for the first 6 mo) or B (70 mg/m2)R (6 mo). A sub-study was introduced in 2018, allowing pts who developed progressive disease (PD) following Tx with BR or VenR to receive the MURANO VenR regimen. PFS was based on investigator assessment. Peripheral blood MRD was analyzed centrally by allele-specific oligonucleotide polymerase chain reaction and/or flow cytometry. Pts were categorized by MRD status as previously reported, using <10-4 threshold for uMRD. MRD conversion was defined as 2 consecutive assays detecting MRD or PD in pts who previously had uMRD. Genomic complexity (GC) and del(17p) status were assessed by array comparative genomic hybridization. GC was defined as ≥3 copy number variations (CNV). All p-values are descriptive. Results: 389 pts were enrolled (VenR, n=194; BR, n=195). With a median f/u of 59.2 (range, 0-71.5) mo, the PFS benefit with VenR over BR was sustained (HR, 0.19 [95% CI: 0.15-0.26]; p<0.0001). Median PFS was 53.6 (95% CI: 48.4-57.0) mo for VenR and 17.0 (95% CI: 15.5-21.7) mo for BR. For pts who completed the full 2 yrs of Ven Tx (n=130), PFS estimates 36 mo post-end of treatment (EOT) were ~51.1% (95% CI: 40.2-61.9). Overall survival (OS) benefit was maintained for pts treated with VenR vs BR (HR, 0.40 [95% CI: 0.26-0.62]; p<0.0001), with 5-yr OS estimates of 82.1% (95% CI: 76.4-87.8) for VenR and 62.2% (95% CI: 54.8-69.6) for BR. Improved OS outcome was observed among the VenR pts that reached EOT without PD and had uMRD (83/118) compared with those with MRD (35/118), with 3-yr post-EOT survival estimates of 95.3% (95% CI: 90.0-100.0) vs 85.0% (95% CI: 72.8-97.2","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"12 1","pages":"11 - 17"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48114187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner 转移性癌症的化疗现状：对高级医师的见解

Journal of the advanced practitioner in oncology

Pub Date : 2021-03-01 DOI: 10.6004/jadpro.2021.12.2.10

K. Hanna, Kelley D. Mayden

© 2021 HarborsideTM Breast cancer is the most frequently diagnosed cancer in the United States and ranks second as the most common cause of cancerrelated death among women (Siegel et al., 2020). According to American Cancer Society (ACS) estimates, approximately 276,480 new cases of breast cancer would have been diagnosed in 2020, and greater than 42,000 deaths would be attributed to breast cancer (ACS, 2020). Although only 7% of all cancer-related deaths are from breast cancer every year, it is the leading cause of death among women between the ages of 40 and 49 years (Siegel et al., 2020). The death rate associated with breast cancer, however, has decreased by 1.3% annually from 2013 to 2017. While improvements in treatment and management coupled with early detection have accounted for the decreased death rate, as of January 2020, there were more than 3.5 million women with a history of breast cancer in the United States (ACS, 2020). Indeed, a vast majority of women with newly diagnosed breast cancer have localized or regional disease that is associated with almost 99% to 85.7% 5-year survival rates, respectively (ACS, 2020). The primary treatment goal for patients with early-stage disease is to reduce the probability of recurrence and spread with primary surgery (lumpectomy or mastectomy) of the breast and regional nodes, with or without radiation therapy and/or in conjunction with neoadjuvant and adjuvant systemic therapy. Despite the successes of these approaches, up to 30% of women with early-stage, nonmetastatic breast cancer will eventually develop distant metastatic disease, and almost 6% of newly diagnosed women have metastatic breast cancer (MBC) at diagnosis (ACS, 2020; Early Breast Cancer Trialists’ Collaborative Group, 2005). It has been estimated that more than 150,000 women are living with MBC, among whom 3 in 4 patients were initially diagnosed with earlier stage disease (Mariotto et al., 2017). Unfortunately for these women, MBC is not curable, and while meaningful improvements have been reported due to the introducJ Adv Pract Oncol 2021;12(suppl 2):3–5 Th is ar tic le is dis tri bu te d u nd er th e t er m s o f t he Cr ea tiv e C om m on s A ttr ibu tio n N on -C om m er cia l N on -D er iva tiv e L ice ns e, wh ich pe rm its un re str ict ed

©2021 HarborsideTM乳腺癌症是美国诊断最频繁的癌症，也是女性癌症相关死亡最常见的原因（Siegel et al.，2020）。根据美国癌症协会（ACS）的估计，2020年约有276480例新的癌症病例被诊断出来，超过42000例死亡将归因于癌症（ACS，2020）。尽管每年只有7%的癌症相关死亡来自癌症，但它是40至49岁女性的主要死亡原因（Siegel et al.，2020）。然而，从2013年到2017年，与癌症相关的死亡率每年下降1.3%。虽然治疗和管理的改善以及早期检测是死亡率下降的原因，但截至2020年1月，美国有350多万女性有乳腺癌症病史（ACS，2020）。事实上，绝大多数新诊断为癌症的女性患有局部或区域性疾病，其5年生存率分别为99%至85.7%（ACS，2020）。早期疾病患者的主要治疗目标是通过乳腺和区域淋巴结的初次手术（肿块切除术或乳房切除术），无论是否进行放射治疗和/或结合新辅助和辅助全身治疗，降低复发和扩散的概率。尽管这些方法取得了成功，但高达30%的早期非转移性癌症女性最终会发展为远处转移性疾病，近6%的新诊断女性在诊断时患有转移性癌症乳腺癌（MBC）（ACS，2020；癌症早期三联体合作小组，2005年）。据估计，超过150000名女性患有MBC，其中四分之三的患者最初被诊断为早期疾病（Mariotto等人，2017）。不幸的是，对于这些女性来说，MBC是无法治愈的，尽管据报道，由于引入了《2021年肿瘤临床杂志》，MBC得到了有意义的改善；12（补充2）：3–5这是对Cr ea tiv e C om m on s A ttr ibu tion n on-C om m er cia l n on-d er iva tiv e l ice ns e的三次分解，这是一个不可分割的过程

{"title":"The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner","authors":"K. Hanna, Kelley D. Mayden","doi":"10.6004/jadpro.2021.12.2.10","DOIUrl":"https://doi.org/10.6004/jadpro.2021.12.2.10","url":null,"abstract":"© 2021 HarborsideTM Breast cancer is the most frequently diagnosed cancer in the United States and ranks second as the most common cause of cancerrelated death among women (Siegel et al., 2020). According to American Cancer Society (ACS) estimates, approximately 276,480 new cases of breast cancer would have been diagnosed in 2020, and greater than 42,000 deaths would be attributed to breast cancer (ACS, 2020). Although only 7% of all cancer-related deaths are from breast cancer every year, it is the leading cause of death among women between the ages of 40 and 49 years (Siegel et al., 2020). The death rate associated with breast cancer, however, has decreased by 1.3% annually from 2013 to 2017. While improvements in treatment and management coupled with early detection have accounted for the decreased death rate, as of January 2020, there were more than 3.5 million women with a history of breast cancer in the United States (ACS, 2020). Indeed, a vast majority of women with newly diagnosed breast cancer have localized or regional disease that is associated with almost 99% to 85.7% 5-year survival rates, respectively (ACS, 2020). The primary treatment goal for patients with early-stage disease is to reduce the probability of recurrence and spread with primary surgery (lumpectomy or mastectomy) of the breast and regional nodes, with or without radiation therapy and/or in conjunction with neoadjuvant and adjuvant systemic therapy. Despite the successes of these approaches, up to 30% of women with early-stage, nonmetastatic breast cancer will eventually develop distant metastatic disease, and almost 6% of newly diagnosed women have metastatic breast cancer (MBC) at diagnosis (ACS, 2020; Early Breast Cancer Trialists’ Collaborative Group, 2005). It has been estimated that more than 150,000 women are living with MBC, among whom 3 in 4 patients were initially diagnosed with earlier stage disease (Mariotto et al., 2017). Unfortunately for these women, MBC is not curable, and while meaningful improvements have been reported due to the introducJ Adv Pract Oncol 2021;12(suppl 2):3–5 Th is ar tic le is dis tri bu te d u nd er th e t er m s o f t he Cr ea tiv e C om m on s A ttr ibu tio n N on -C om m er cia l N on -D er iva tiv e L ice ns e, wh ich pe rm its un re str ict ed","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"12 1","pages":"3 - 5"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49390027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Budd-Chiari Syndrome as Initial Manifestation of Polycythemia Vera: Complexities in the Management of Younger Patients Budd-Chiari综合征是真性红细胞增多症的初始表现:年轻患者管理的复杂性

Journal of the advanced practitioner in oncology

Pub Date : 2020-10-01 DOI: 10.6004/jadpro.2020.11.7.12

Pamela Lyle, PA Lindsey E. Kalhagen

引用次数: 0

Managing Thrombosis in Polycythemia Vera: The Advanced Practitioner Perspective 管理血栓在真性红细胞增多症:先进的从业者的观点

Journal of the advanced practitioner in oncology

Pub Date : 2020-10-01 DOI: 10.6004/jadpro.2020.11.7.11

L. Lyle, Pa-C

引用次数: 0

Optimizing Treatment Strategies in Patients With Polycythemia Vera Who Develop a Thrombotic Event on Frontline Therapy 真性红细胞增多症患者在一线治疗中发生血栓事件的优化治疗策略

Journal of the advanced practitioner in oncology

Pub Date : 2020-10-01 DOI: 10.6004/jadpro.2020.11.7.13

Pamela L. Lyle, PA Julie Huynh-Lu

引用次数: 0

ASH Highlights and Commentary: Chronic Lymphocytic Leukemia ASH亮点与评论：慢性淋巴细胞白血病

Journal of the advanced practitioner in oncology

Pub Date : 2020-04-01 DOI: 10.6004/jadpro.2020.11.3.22

引用次数: 0

ASH Highlights and Commentary: Acute Myeloid Leukemia and Myelodysplastic Syndromes ASH亮点和评论：急性髓细胞白血病和骨髓增生异常综合征

Journal of the advanced practitioner in oncology

Pub Date : 2020-04-01 DOI: 10.6004/jadpro.2020.11.3.23

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of the advanced practitioner in oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀